ライフサイエンスコーパス: antidiabetic drug

1 of any insulin regimen (with or without oral antidiabetic drugs).

2 for the commercial synthesis of Januvia, an antidiabetic drug.

3 rget for the 2, 4-thiazolidinedione class of antidiabetic drugs.

4 o fatty acids, lipid-derived metabolites and antidiabetic drugs.

5 ared with commonly used combinations of oral antidiabetic drugs.

6 ere non-smokers, aged >/=40 years, and using antidiabetic drugs.

7 glycemia through daily dosing of one or more antidiabetic drugs.

8 pment of better and safer PPARgamma-mediated antidiabetic drugs.

9 e 2 diabetes inadequately controlled on oral antidiabetic drugs.

10 uately controlled on basal insulin plus oral antidiabetic drugs.

11 d suggest an approach for the development of antidiabetic drugs.

12 merged as a major potential target for novel antidiabetic drugs.

13 rter 2 (SGLT2) inhibitors are a new class of antidiabetic drugs.

14 ated with basal insulin with or without oral antidiabetic drugs.

15 1)R receptor agonist 2-MeS-ADP, as potential antidiabetic drugs.

16 ed remission to a non-diabetic state and off antidiabetic drugs.

17 te effects of the PPARgamma agonist class of antidiabetic drugs.

18 onse to thiazolidinediones (TZDs), which are antidiabetic drugs.

19 lar target of the thiazolidinedione class of antidiabetic drugs.

20 ment include metabolic-modulating agents and antidiabetic drugs.

21 ids and the thiazolidinedione (TZD) class of antidiabetic drugs.

22 get for the thiazolidinedione (TZD) class of antidiabetic drugs.

23 ell as the target of thiazolidinedione (TZD) antidiabetic drugs.

24 get for the thiazolidinedione (TZD) class of antidiabetic drugs.

25 many bioactive natural products, such as the antidiabetic drug acarbose, the crop protectant validamy

26 f action is unique in that no other approved antidiabetic drugs act via this mechanism, and raises th

27 ollowing the recent therapeutic successes of antidiabetic drugs aimed at either mimicking GLP-1 or pr

28 t PPARgamma ligands are clinically effective antidiabetic drugs, although side effects limit their ut

29 relationship between cumulative use of other antidiabetic drugs and either outcome.

30 izes the anticancer drug paclitaxel, certain antidiabetic drugs, and endogenous substrates, including

31 that include the thiazolidinedione class of antidiabetic drugs, as well as derivatives of polyunsatu

32 Moreover, in subjects not taking oral antidiabetic drugs, baseline osteocalcin concentrations

33 s the next generation of insulin-sensitizing antidiabetic drugs, because the currently marketed PPARg

34 f incretin-based drugs as compared with oral antidiabetic-drug combinations among patients with a his

35 drugs, as compared with those receiving oral antidiabetic-drug combinations, were estimated by means

36 receptor for the thiazolidinedione class of antidiabetic drugs, controls mitochondrial network fragm

37 Metformin (Met) is an approved antidiabetic drug currently being explored for repurposi

38 ch, it represents a target for anticancer or antidiabetic drug development.

39 agon-like peptide 1 (GLP-1) receptor via the antidiabetic drug exenatide led to improvements in both

40 These data demonstrate that two antidiabetic drugs exert opposite effects on the PepT1 t

41 prescribed other diabetes treatments (other antidiabetic drug-exposed group).

42 PD compared to 517 individuals in the other antidiabetic drug-exposed group.

43 lipid homeostasis and is the target for the antidiabetic drugs GI262570 and the thiazolidinediones (

44 istration industry guidance for licensing of antidiabetic drugs greatly increased the number of cardi

45 Improved management of antithrombotic and antidiabetic drugs has the potential to reduce hospitali

46 l-tolerated and Federal Drug Agency-approved antidiabetic drug, has positive effects on insulin resis

47 nists such as the thiazolidinedione class of antidiabetic drugs have a new target cell, the platelet.

48 Antidiabetic drugs have been found to have various effec

49 Because currently available antiobesity and antidiabetic drugs have limited efficacy and/or safety c

50 with placebo, subcutaneous insulin, or oral antidiabetic drugs in people with type 1 or type 2 diabe

51 ibitors have been approved as a new class of antidiabetic drugs in type 2 diabetes mellitus, and stud

52 e, Lehraiki et al. report that metformin, an antidiabetic drug, inhibited melanogenesis, in vitro and

53 azolidinedione class of insulin-sensitizing, antidiabetic drugs interacts with peroxisome proliferato

54 The antidiabetic drug metformin (which is derived from an he

55 Treatment with the antidiabetic drug metformin during ovariectomy-induced w

56 The antidiabetic drug metformin exhibits both chemopreventiv

57 The effect of the antidiabetic drug metformin on tumor growth was investig

58 ment of pregnant p53d/d mice with either the antidiabetic drug metformin or the antioxidant resveratr

59 that activation of AMPK with the widely used antidiabetic drug metformin or with the AMP mimetic 5-am

60 The antidiabetic drug metformin stimulates AMP-activated pro

61 genous TAK1 was activated by oligomycin, the antidiabetic drug metformin, 5-aminoimidazole-4-carboxam

62 n detail the effects of the most widely used antidiabetic drug metformin.

63 nefits of exercise and is the target for the antidiabetic drug metformin.

64 , and AMPK is the target for the widely used antidiabetic drug metformin.

65 e first time demonstrate a novel role of the antidiabetic drug, metformin, in suppressing uveitis in

66 to the carboxylic acid group of the type II antidiabetic drugs nateglinide and meglitinide were synt

67 Troglitazone, a new antidiabetic drug of the thiazolidinedione class, acts a

68 ffective utilization of E. maxima as an oral antidiabetic drug or functional food ingredient with a p

69 l/L who were being treated with diet or oral antidiabetic drugs or had a total daily insulin dose of

70 azole-4-carboxamide riboside (AICAR), by the antidiabetic drug phenformin, or by muscle contraction.

71 We further show that the antidiabetic drug phenformin, which activates AMP kinase

72 debated for several years as to whether the antidiabetic drug pioglitazone increases the risk for bl

73 Binding of the thiazolidinedione antidiabetic drug pioglitazone led to the discovery of a

74 oup of hybrid nitric oxide-releasing type II antidiabetic drugs possessing a 1-(pyrrolidin-1-yl)diaze

75 The association between antidiabetic drug prescriptions and outcomes was assesse

76 ylase kinase by a mechanism analogous to the antidiabetic drug proglycosyn.

77 d ( approximately 10-fold) treatment, or the antidiabetic drug rosiglitazone, all known PPAR activato

78 rompted us to investigate the effects of two antidiabetic drugs, rosiglitazone and metformin, on PepT

79 Glyburide (GLB) is an antidiabetic drug routinely used to treat gestational di

80 key intermediate in the preparation of oral antidiabetic drug Saxagliptin is discussed with an empha

81 Explorations of apoA-I as a novel antidiabetic drug should extend to treatments of diabeti

82 This important NR complex is a target for antidiabetic drugs since it binds to DNA and functions a

83 The antidiabetic drugs sitagliptin and exenatide, which inhi

84 Antidiabetic drugs such as peroxisome proliferator-activ

85 rational basis for the development of novel antidiabetic drugs targeting this class of receptors.

86 Troglitazone was a widely used antidiabetic drug that activates PPARgamma.

87 iazolidinedione derivative, is a widely used antidiabetic drug that binds and activates peroxisome pr

88 Metformin is a widely used antidiabetic drug that exerts cardiovascular protective

89 eneration biguanide, is a commonly used oral antidiabetic drug that has been shown recently to stimul

90 Troglitazone is a new oral antidiabetic drug that increases the sensitivity of peri

91 r3 O(OCOEt)6 (OH2 )3 ](+) (A), a prospective antidiabetic drug that undergoes similar H2 O2 induced o

92 l can be gradually purged by the glitazones, antidiabetic drugs that are agonists of peroxisome proli

93 lar target of the thiazolidinedione class of antidiabetic drugs that has many side effects.

94 Thiazolidinediones are a novel class of antidiabetic drugs that improve insulin sensitivity in t

95 e defects predict sensitivity to biguanides, antidiabetic drugs that inhibit OXPHOS, when cancer cell

96 The antidiabetic drugs thiazolidinediones bind and activate

97 lization and lectin analysis of acarbose, an antidiabetic drug, to dabsyl-tagged enzyme substrates to

98 r has been further highlighted by reports of antidiabetic drugs treating or promoting cancer.

99 ntiation following exposure to BDE-47 or the antidiabetic drug troglitazone (TROG).

100 which have the potential as antiasthmatic or antidiabetic drugs, we have synthesized and screened a v

101 to maximal metformin therapy, all noninsulin antidiabetic drugs were associated with similar HbA(1c)

102 All other antidiabetic drugs were discontinued on admission.

103 armful consequence of this widely prescribed antidiabetic drug when used as a monotherapy in elderly

104 receptor for the thiazolidinedione class of antidiabetic drugs, which includes troglitazone and rosi

105 e development of GPR119 agonists as new oral antidiabetic drugs will be discussed.

106 Metformin is the first-line antidiabetic drug with over 100 million users worldwide,

107 approach for the rational design of type II antidiabetic drugs with a reduced risk of contraindicate

108 tformin is the most commonly prescribed oral antidiabetic drug, with well-documented beneficial preve